283 related articles for article (PubMed ID: 36685508)
1. Comprehensive analysis of cuproptosis-related lncRNAs for prognostic significance and immune microenvironment characterization in hepatocellular carcinoma.
Li D; Jin S; Chen P; Zhang Y; Li Y; Zhong C; Fan X; Lin H
Front Immunol; 2022; 13():991604. PubMed ID: 36685508
[TBL] [Abstract][Full Text] [Related]
2. A novel cuproptosis-related lncRNA signature predicts the prognosis and immunotherapy for hepatocellular carcinoma.
Liu Y; Jiang J
Cancer Biomark; 2023; 37(1):13-26. PubMed ID: 37005878
[TBL] [Abstract][Full Text] [Related]
3. Comprehensive analysis of cuproptosis-related lncRNAs in immune infiltration and prognosis in hepatocellular carcinoma.
Liu C; Wu S; Lai L; Liu J; Guo Z; Ye Z; Chen X
BMC Bioinformatics; 2023 Jan; 24(1):4. PubMed ID: 36597032
[TBL] [Abstract][Full Text] [Related]
4. A Cuproptosis-Related LncRNA Risk Model for Predicting Prognosis and Immunotherapeutic Efficacy in Patients with Hepatocellular Carcinoma.
Wang S; Bai H; Fei S; Miao B
Biochem Genet; 2023 Oct; ():. PubMed ID: 37898914
[TBL] [Abstract][Full Text] [Related]
5. An integrative analysis revealing cuproptosis-related lncRNAs signature as a novel prognostic biomarker in hepatocellular carcinoma.
Chen X; Sun M; Feng W; Chen J; Ji X; Xie M; Huang W; Chen X; Zhang B; Nie Y; Fan D; Wu K; Xia L
Front Genet; 2023; 14():1056000. PubMed ID: 36845390
[No Abstract] [Full Text] [Related]
6. Prognostic analysis of hepatocellular carcinoma based on cuproptosis -associated lncRNAs.
Wei M; Lu L; Luo Z; Ma J; Wang J
BMC Gastroenterol; 2024 Apr; 24(1):142. PubMed ID: 38654165
[TBL] [Abstract][Full Text] [Related]
7. Identification of a cuproptosis and copper metabolism gene-related lncRNAs prognostic signature associated with clinical and immunological characteristics of hepatocellular carcinoma.
Yuan W; Xiao JH; Zhang JS; Mao BL; Wang PZ; Wang BL
Front Oncol; 2023; 13():1153353. PubMed ID: 37056336
[TBL] [Abstract][Full Text] [Related]
8. A novel cuproptosis-related prognostic lncRNA signature for predicting immune and drug therapy response in hepatocellular carcinoma.
Chen S; Liu P; Zhao L; Han P; Liu J; Yang H; Li J
Front Immunol; 2022; 13():954653. PubMed ID: 36189204
[TBL] [Abstract][Full Text] [Related]
9. Signature construction and molecular subtype identification based on cuproptosis-related genes to predict the prognosis and immune activity of patients with hepatocellular carcinoma.
Peng X; Zhu J; Liu S; Luo C; Wu X; Liu Z; Li Y; Yuan R
Front Immunol; 2022; 13():990790. PubMed ID: 36248822
[TBL] [Abstract][Full Text] [Related]
10. Cuproptosis-Related LncRNA-Based Prediction of the Prognosis and Immunotherapy Response in Papillary Renal Cell Carcinoma.
Pang Y; Wang Y; Zhou X; Ni Z; Chen W; Liu Y; Du W
Int J Mol Sci; 2023 Jan; 24(2):. PubMed ID: 36674979
[TBL] [Abstract][Full Text] [Related]
11. Cuproptosis-Related LncRNA Signature for Predicting Prognosis of Hepatocellular Carcinoma: A Comprehensive Analysis.
Chen Q; Sun T; Wang G; Zhang M; Zhu Y; Shi X; Ding Z
Dis Markers; 2022; 2022():3265212. PubMed ID: 36452343
[TBL] [Abstract][Full Text] [Related]
12. Identification of cuproptosis-related lncRNA prognostic signature for osteosarcoma.
Liu B; Liu Z; Feng C; Li C; Zhang H; Li Z; Tu C; He S
Front Endocrinol (Lausanne); 2022; 13():987942. PubMed ID: 36313774
[TBL] [Abstract][Full Text] [Related]
13. Prognostic and Immunological Significance of the Molecular Subtypes and Risk Signatures Based on Cuproptosis in Hepatocellular Carcinoma.
Tang X; Ren X; Huang T; Miao Y; Ha W; Li Z; Yang L; Mi D
Mediators Inflamm; 2023; 2023():3951940. PubMed ID: 37124062
[TBL] [Abstract][Full Text] [Related]
14. Construction and systematic evaluation of a machine learning-based cuproptosis-related lncRNA score signature to predict the response to immunotherapy in hepatocellular carcinoma.
Lu D; Liao J; Cheng H; Ma Q; Wu F; Xie F; He Y
Front Immunol; 2023; 14():1097075. PubMed ID: 36761763
[TBL] [Abstract][Full Text] [Related]
15. Identification and development of a novel risk model based on cuproptosis-associated RNA methylation regulators for predicting prognosis and characterizing immune status in hepatocellular carcinoma.
Li D; Shi Z; Liu X; Jin S; Chen P; Zhang Y; Chen G; Fan X; Yang J; Lin H
Hepatol Int; 2023 Feb; 17(1):112-130. PubMed ID: 36598701
[TBL] [Abstract][Full Text] [Related]
16. Cuproptosis-Related Signature Predicts the Prognosis, Tumor Microenvironment, and Drug Sensitivity of Hepatocellular Carcinoma.
Qi X; Guo J; Chen G; Fang C; Hu L; Li J; Zhang C
J Immunol Res; 2022; 2022():3393027. PubMed ID: 36438201
[TBL] [Abstract][Full Text] [Related]
17. Cuproptosis-related lncRNA scoring system to predict the clinical outcome and immune landscape in pancreatic adenocarcinoma.
Huang Y; Gong P; Su L; Zhang M
Sci Rep; 2023 Nov; 13(1):20870. PubMed ID: 38012210
[TBL] [Abstract][Full Text] [Related]
18. A cuproptosis random forest cox score model-based evaluation of prognosis, mutation characterization, immune infiltration, and drug sensitivity in hepatocellular carcinoma.
Liu R; Liu Y; Zhang F; Wei J; Wu L
Front Immunol; 2023; 14():1146411. PubMed ID: 37063920
[TBL] [Abstract][Full Text] [Related]
19. A Cuproptosis-Related lncRNAs Signature Could Accurately Predict Prognosis in Patients with Clear Cell Renal Cell Carcinoma.
Zhang W; Wang H; Wang W; Xue H; Qiao M; Song L; Wang S; Ren Z; Ma Z
Anal Cell Pathol (Amst); 2022; 2022():4673514. PubMed ID: 36588797
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive analysis of cuproptosis-related long non-coding RNAs in prognosis, immune microenvironment infiltration and chemotherapy response of hepatocellular carcinoma.
Ren H; Zheng J; Zhu Y; Wang L; Liu J; Xu H; Dong J; Zhang S
Medicine (Baltimore); 2023 Dec; 102(50):e36611. PubMed ID: 38115286
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]